Illuminating the Druggable Genome Resource Dissemination and Outreach Center (IDG-RDOC)

项目总结 随着人类基因组计划(HGP)接近成功结束，美国国立卫生研究院正在进行 制定路线图，该路线图演变为共同基金。处于这些倡议前沿的是 促进技术发展的生物医学工程研究伙伴关系(BRP)。对于 BRP，Sklar领导了高通量流式细胞术的发展，这是一种过渡到 进入分子文库计划(MLP)，这是HGP的逻辑继承者，以开发小分子探针 寻找新发现的基因组靶点。为共同基金照亮可用药基因组(IDG) 成为下一个顺理成章的继承者，为进一步研究确定基因组目标的优先顺序。技术 通过Sklar的BRP高级成为与Oprea合作的基础，从而在10年内 通过试验和生产阶段参与MLP，由Sklar领导行政和 实验室工作和Oprea领导数据科学工作。在MLP接近尾声时，Oprea、Sklar和 Schürer自试点阶段以来一直是MLP的一部分，他加入了BARD倡议的力量(2012- 14)，并再次进入第一阶段(2015-17)和IDG第二阶段提案(2018-24)。 尽管在开发新疗法及其巨大的医疗和社会效益方面取得了稳步进展， 目前的药物只针对人类蛋白质组的一小部分。甚至临床开发中的药物和大多数 临床前药物发现研究忽略了可药物蛋白质组的很大一部分。通过 开发、广泛传播和使用社区科学资源，IDG计划的重点是 正在推进研究人类蛋白质的研究，这些蛋白质的公开信息或活跃研究是 目前缺乏，以催化新生物学的发现，特别关注未被研究的 蛋白激酶、离子通道和非嗅觉GPCR族的成员。 我们来自新墨西哥大学和迈阿密大学的高度协调的团队将建立 IDG资源传播和外联中心(RDoC)，以促进广泛接触财团- 生成的数据和资源，并为IDG财团及其 与外部合作伙伴的关系。IDG-RDoC将与所有IDG财团调查人员合作，收集 并整理有关IDG财团正在开发的关键工具和试剂的信息，以及 通过IDG门户网站进行传播。具体来说，我们将：(1)协调和支持IDG财团 通过经验丰富的行政团队；(2)促进和协调外部伙伴关系、外联和 与IDG计划活动有关的培训；以及(3)制定和实施数据标准、政策、业务、 和工具，用于收集、整理、识别和传播IDG生成的资源(扩展) NIH公平(可发现、可访问、可归因性、可互操作、可重复使用、可重复使用)原则。 1“

PROJECT SUMMARY As the Human Genome Project (HGP) approached its successful conclusion, NIH was in the process of formulating the Roadmap, which evolved into the Common Fund. At the leading edge of these initiatives was the Biomedical Engineering Research Partnership (BRP), which promoted technology development. For the BRP, Sklar led the development of high throughput flow cytometry, a screening technology which transitioned into the Molecular Libraries Program (MLP), a logical successor to the HGP, to develop small molecule probes for newly discovered genomic targets. For the Common Fund, Illuminating the Druggable Genome (IDG) became the next logical successor to prioritize genomic targets for further investigation. The technology advanced via the BRP by Sklar became a foundation for the collaboration with Oprea resulting in 10 years of participation in the MLP through both pilot and production phases, with Sklar leading both administrative and laboratory efforts and Oprea leading the data science efforts. Toward the end of the MLP, Oprea, Sklar, and Schürer, who had also been part of the MLP since the pilot phase, joined forces for the BARD initiative (2012- 14) and again in Phase I (2015-17) and this Phase II IDG proposal (2018-24). Despite steady progress in developing novel therapeutics and their enormous medical and societal benefits, current drugs target only a small fraction of the human proteome. Even drugs in clinical development and most preclinical drug discovery research ignore a significant portion of the druggable proteome. Through the development, broad dissemination, and use of community scientific resources, the IDG program is focused on advancing research to study human proteins for which publicly available information or active research is currently lacking, in order to catalyze the discovery of novel biology with a particular focus on understudied members of the protein kinase, ion channel, and non-olfactory GPCR families. Our highly-coordinated team from the University of New Mexico and the University of Miami will establish the IDG Resource Dissemination and Outreach Center (RDOC) to facilitate widespread access to consortium- generated data and resources as well as to serve the overall administration of the IDG Consortium and its relationships with external partners. The IDG-RDOC will work with all IDG Consortium investigators to collect and curate information regarding critical tools and reagents being developed by the IDG Consortium and disseminate them through the IDG Portal. Specifically we will: (i) coordinate and support the IDG consortium via a highly experienced administrative team; (ii) facilitate and coordinate external partnerships, outreach, and training related to IDG program activities; and (iii) develop and implement data standards, policies, operations, and tools to collect, curate, identify, and disseminate IDG-generated resources in accordance with (extended) NIH FAIR (Findable, Accessible, Attributable, Interoperable, Reusable, Reproducible) principles. 1"